Literature DB >> 2984300

Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation.

J Musial, S Niewiarowski, D Hershock, T A Morinelli, R W Colman, L H Edmunds.   

Abstract

In vitro recirculation of fresh human heparinized blood in an extracorporeal circuit with a membrane oxygenator decreased fibrinogen-induced platelet aggregation and diminished the number of fibrinogen receptors and glycoprotein IIb/IIIa (GPIIb/GPIIIa) antigenic sites on the platelet surface. In seven experiments, the mean +/- SD Km value for fibrinogen (i.e., molar concentration of fibrinogen required to cause 50% of the maximal rate of aggregation) was 1.58 X 10(-7) mol/L +/- 0.68 X 10(-7) mol/L. After recirculation, this value increased to 3.8 X 10(-7) mol/L +/- 1.94 X 10(-7) mol/L (P less than or equal to 0.025). The maximal aggregation rate of chymotrypsin-treated platelets decreased by 40% after 2 hours of recirculation (P less than or equal to 0.025). The number of fibrinogen receptors on platelets, which were treated with chymotrypsin after a recirculation, decreased from 41,370 +/- 24,000 to 13,230 +/- 10,230/platelet under the same conditions (P less than or equal to 0.025). The number of antigenic sites for monoclonal antibody reacting with GPIIb/GPIIIa complex of adenosine diphosphate-stimulated platelets decreased from 34,200 +/- 5,940 to 19,500 +/- 9,680/platelet after recirculation (P less than or equal to 0.025). Prostaglandin E1 (0.3 mumol/L) in the perfusion circuit preserved the ability of platelets to react with fibrinogen. In conclusion, the loss of fibrinogen receptors from the surface of platelet membranes results from the interaction of platelets with the surfaces of perfusion circuits.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984300

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  7 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

Review 2.  AKI associated with cardiac surgery.

Authors:  Robert H Thiele; James M Isbell; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

3.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Authors:  C S Rinder; H M Rinder; B R Smith; J C Fitch; M J Smith; J B Tracey; L A Matis; S P Squinto; S A Rollins
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

Review 4.  Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.

Authors:  R Davis; R Whittington
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

5.  Cardiac bypass surgery with haemorrhagic endocrine sequelae.

Authors:  R Khardori; R C Bussing; G M Burns; N G Soler
Journal:  Postgrad Med J       Date:  1987-06       Impact factor: 2.401

6.  Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery.

Authors:  J N George; E B Pickett; S Saucerman; R P McEver; T J Kunicki; N Kieffer; P J Newman
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

7.  Sutureless Perceval Aortic Valve Versus Conventional Stented Bioprostheses: Meta-Analysis of Postoperative and Midterm Results in Isolated Aortic Valve Replacement.

Authors:  Massimo Meco; Andrea Montisci; Antonio Miceli; Paolo Panisi; Francesco Donatelli; Silvia Cirri; Matteo Ferrarini; Antonio Lio; Mattia Glauber
Journal:  J Am Heart Assoc       Date:  2018-02-16       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.